ABCL
AbCellera Biologics Inc. (NASDAQ)
Healthcare — Biotechnology
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Price History
Fundamentals
| Market Cap | $2.34B |
| P/E Ratio (TTM) | - |
| Forward P/E | -10.65 |
| EPS (TTM) | $-0.48 |
| Dividend Yield | - |
| Profit Margin | -181.74% |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | Strong Buy 1.3 |
| Analyst Target | $10.43 |
| Analysts | 7 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 79.1 |
| Beta | 1.20 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | - |
| 52-Week Low | - |
| 50-Day Avg | - |
| 200-Day Avg | - |
| Avg Volume | - |
| Volume | - |
Performance Analysis
NEUTRALABCL presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 01, 2026 15:01 UTC
Back to Screener Export Report